The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
Open accessAbstract
Historically, treatment of patients with cancer using chemotherapeutic agents has been associated with debilitating and systemic toxicities, poor bioavailability, and unfavorable pharmacokinetics. Nanotechnology-based drug delivery systems, on the other hand, can specifically target cancer cells while avoiding their healthy neighbors, avoid rapid clearance from the body, and be administered without toxic solvents. They hold immense potential in addressing all of these issues, which has hampered further development of chemotherapeutics. Furthermore, such drug delivery systems will lead to cancer therapeutic modalities that are not only less toxic to the patient but also significantly more efficacious. In addition to established therapeutic modes of action, nanomaterials are opening up entirely new modalities of cancer therapy, such as photodynamic and hyperthermia treatments. Furthermore, nanoparticle carriers are also capable of addressing several drug delivery problems that could not be effectively solved in the past and include overcoming formulation issues, multidrug-resistance phenomenon, and penetrating cellular barriers that may limit device accessibility to intended targets, such as the blood–brain barrier. The challenges in optimizing design of nanoparticles tailored to specific tumor indications still remain; however, it is clear that nanoscale devices carry a significant promise toward new ways of diagnosing and treating cancer. This review focuses on future prospects of using nanotechnology in cancer applications and discusses practices and methodologies used in the development and translation of nanotechnology-based therapeutics. Clin Cancer Res; 18(12); 3229–41. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Self-citationOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., & Redemann, C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11460 · Cited by 1,620
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01426-1 · Cited by 1,263
Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B., & McNeil, S. E. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800032f · Cited by 1,022
Sterically stabilized liposomes
Woodle, M. C., & Lasic, D. D. (1992) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(92)90038-c · Cited by 954
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers
Gu, F., Zhang, L., Teply, B. A., Mann, N., Wang, A., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711714105 · Cited by 715
Cited by
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Metadata
- Authors
- Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J., & Grodzinski, P.
- Venue
- Clinical Cancer Research
- Published
- 2012-06-14
- Volume
- 18
- Issue
- 12
- Pages
- 3229-3241
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2168278139
- Cited by
- 275
- References
- 72
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-2938
- The paper
- Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J., & Grodzinski, P. (2012). Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-2938
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.